Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

34.92USD
16 Nov 2018
Change (% chg)

-- (--)
Prev Close
$34.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,591,707
52-wk High
$47.81
52-wk Low
$30.34

Latest Key Developments (Source: Significant Developments)

Theravance, Mylan Expect YUPELRI To Be Available To U.S. COPD Patients Before End Of The Year
Saturday, 10 Nov 2018 

Nov 9 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA AND MYLAN RECEIVE FDA APPROVAL FOR YUPELRI™ (REVEFENACIN) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.THERAVANCE BIOPHARMA INC - CO, MYLAN EXPECT YUPELRI TO BE AVAILABLE TO COPD PATIENTS IN U.S. BEFORE END OF THE YEAR.  Full Article

FDA Approves Theravance Biopharma's COPD Drug Yupelri
Friday, 9 Nov 2018 

Nov 9 (Reuters) - U.S. Food And Drug Administration::U.S. FDA - APPROVES THERAVANCE BIOPHARMA'S COPD DRUG YUPELRI.  Full Article

Mylan's Statement On Generic Advair ANDA Status
Tuesday, 23 Oct 2018 

Oct 22 (Reuters) - Mylan NV ::MYLAN'S STATEMENT ON GENERIC ADVAIR ANDA STATUS.MYLAN ON GENERIC ADVAIR ANDA STATUS - CONFIRMS HAS NOT RECEIVED ANY NEW INFORMATION REQUEST OR CRL FROM FDA.MYLAN ON GENERIC ADVAIR ANDA STATUS SAYS CONTINUES TO BELIEVE THAT FDA APPROVAL IS IMMINENT.  Full Article

Biocon & Mylan Announce Positive CHMP Opinion For Ogivri
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Biocon Ltd ::SAYS BIOCON AND MYLAN ANNOUNCE POSITIVE CHMP OPINION FOR OGIVRI, BIOSIMILAR TRASTUZUMAB.  Full Article

Mylan Adds To Women's Healthcare Portfolio With Launch Of Generic Depo-Provera® Injection
Friday, 19 Oct 2018 

Oct 18 (Reuters) - Mylan NV ::MYLAN ADDS TO WOMEN'S HEALTHCARE PORTFOLIO WITH LAUNCH OF GENERIC DEPO-PROVERA® INJECTION.MYLAN NV - U.S. LAUNCH OF MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION USP, 150 MG/ML SINGLE-DOSE VIAL.  Full Article

Mylan NV Plans To Launch HIV Self-Test In Global Markets In Early 2019
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Mylan NV ::MYLAN NV - STRATEGIC PARTNERSHIP TO COMMERCIALIZE CE-MARKED IN VITRO HIV RAPID DIAGNOSTIC TESTS FOR SELF-TESTING IN LOW- AND MIDDLE-INCOME COUNTRIES.MYLAN NV - HAS EXCLUSIVE RIGHTS TO COMMERCIALIZE PRODUCTS IN OVER 100 COUNTRIES IN AFRICA, ASIA, MIDDLE EAST, CIS AND LATIN AMERICA.MYLAN NV - PLANS TO LAUNCH MYLAN HIV SELF-TEST IN GLOBAL MARKETS IN EARLY 2019.  Full Article

Sandoz Wins U.S. FDA's Approval For Busulfan - FDA Wesbite
Saturday, 22 Sep 2018 

Sept 21 (Reuters) - FDA ::SANDOZ INC WINS U.S. FDA'S APPROVAL FOR BUSULFAN - FDA WESBITE.  Full Article

Mylan Launches Authorized Generic Of Ampyra Tablets
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Mylan NV ::MYLAN LAUNCHES AUTHORIZED GENERIC OF AMPYRA® TABLETS.MYLAN NV - ANNOUNCED U.S. LAUNCH OF DALFAMPRIDINE EXTENDED-RELEASE TABLETS, 10 MG.  Full Article

Mylan Adds To Cardiovascular Portfolio With Launch Of First Generic Of Brevibloc Injection In Single-Dose Bags
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Mylan NV ::MYLAN ADDS TO CARDIOVASCULAR PORTFOLIO WITH LAUNCH OF FIRST GENERIC OF BREVIBLOC® INJECTION IN SINGLE-DOSE BAGS.MYLAN - LAUNCH OF ESMOLOL HYDROCHLORIDE IN SODIUM CHLORIDE INJECTION, 2,500 MG/250 ML SINGLE-DOSE PLASTIC BAG & 2,000 MG/100 ML SINGLE-DOSE PLASTIC BAG.  Full Article

Mylan Closes Deal With Novartis To Commercialize Certain Global Cystic Fibrosis Products
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Mylan NV ::MYLAN - CLOSED DEAL WITH NOVARTIS TO BUY WORLDWIDE RIGHTS TO COMMERCIALIZE GLOBAL CYSTIC FIBROSIS PRODUCTS CONSISTING OF TOBI PODHALER & TOBI SOLUTION.  Full Article

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.